Pharmaceuticals

Viatris

FDA Accepts Viatris Meloxicam NDA, PDUFA Date Set for Dec 2026

Viatris released FY2026 Q1 earnings on May 7 During-Market (EST), actual revenue USD 3.517 B (forecast USD 3.357 B), actual EPS USD 0.15 (forecast USD -0.8445)

Viatris Q1 2026 Revenue and Earnings Per Share Exceed Expectations

Viatris Reports Q1 2026 Earnings and Reiterates Full-Year Guidance

Viatris Announces Positive Phase III Trial Results for Low-Dose Estrogen Contraceptive Patch MR-100A-01

Viatris to Release FY2026 Q1 Earnings on May 7 During-Market EST, Forecast Revenue USD 3.357 B, EPS USD -0.8445

Viatris Inc. Secures Approval for Effexor SR Capsules in Japan

Viatris Inc. Secures Approval for Effexor® in Japan

Viatris Releases Financial Projections for 2025 and 2026

FactSet: VTRS-US EPS Forecast Revised Down to $2.46 in 2026

Viatris released FY2025 Q4 earnings on February 26 During-Market (EST), actual revenue USD 3.704 B (forecast USD 3.526 B), actual EPS USD -0.295 (forecast USD -0.0316)

Viatris Reports Q4 Revenue Growth Exceeding Analysts' Expectations and Outlines 2026 Revenue Targets

Viatris to release FY2025 Q4 earnings on February 26, 2026, during market hours EST, with forecasted revenue of USD 3.526 B and EPS of USD -0.0316

Viatris Launches Innovative INPEFA® for Heart Failure Treatment

VTRS-US Stock Target Price Raised to 13.5 USD

Viatris Receives FDA Approval for Generic Drug and Acceptance of New Drug Application, Japanese PMDA Accepts Application

Viatris Inc. Completes Transaction to Receive $400 Million in Cash and Biocon Limited Shares

Viatris Inc. to Participate in Two Healthcare Conferences

Viatris Collaborates with Multiple Organizations to Combat Antimicrobial Resistance

US Bank Securities Analyst Maintains Viatris Sell Rating, Target Price at $9.00

OPTIMI HEALTH CORP

HCW Biologics

GCL Global

Silexion Therapeutics

Vida Global

MetaVia

BiomX

Micware

Tradr 2X Long XNDU Daily ETF

EMMIS ACQUISITION CORP. ORD USD0.0001 (S/R 12/09/2030)

Ordinary dividend (cash)

Ex Date: 2026.05.22 (EST), Cash dividend 0.12 USD

VTRS

Viatris Inc. (VTRS) shares fell 2.00% to $16.17 on Tuesday, underperforming the market as the S&P 500 and Dow Jones also declined. The stock is currently 7.76% below its 52-week high of $17.53 reached on May 14th, with trading volume at 11.9 million, surpassing its 50-day average of 11.1 million.

MarketWatch Automated

S&P 500

Dow Jones Industrial Average

Factset Research

Viatris Inc. Stock Falls Tuesday, Underperforms Market

Viatris Inc. announced that the U.S. FDA has accepted its New Drug Application for fast-acting meloxicam (MR-107A-02) to treat moderate-to-severe acute pain, with a PDUFA goal date set for Dec. 27, 2026. This non-opioid treatment aims to address the significant public health need for effective pain management, supported by positive Phase 3 trial results. The drug is designed for rapid absorption and aims to reduce opioid usage among patients.

StockTitan

U.S. FDA Accepts Viatris New Drug Application for Fast-Acting Meloxicam for the Treatment of Moderate-to-Severe Acute Pain | VTRS Stock News

ARKG

IBBQ

Shares of Viatris Inc. (VTRS) rose 1.16% to $17.37 on Wednesday, outperforming the mixed stock market, where the S&P 500 increased by 0.58% and the Dow Jones fell by 0.14%. This marks the second consecutive day of gains for Viatris, which is now just 0.91% below its 52-week high of $17.53 reached on May 8th. Trading volume was 14.3 million, surpassing the 50-day average of 11.2 million.

VG Health

Health Care Select Sector SPDR

iShares Biotechnology ETF

iShares US Pharma

Ark Genomic Revolution ETF

iShares Global Healthcare

Invesco Nasdaq Biotechnology ETF

Viatris Inc. Stock Rises Wednesday, Outperforms Market

Shares of Viatris Inc. (VTRS) rose 1.48% to $17.17 on Tuesday, outperforming the market despite a mixed trading session. The Dow Jones Industrial Average increased by 0.11%, while the S&P 500 Index fell by 0.16%. This rise ended a two-day losing streak for Viatris, which is now 2.05% below its 52-week high of $17.53 reached on May 8th. Trading volume was 12.3 million, surpassing the 50-day average of 11.2 million.

Viatris Inc. Stock Rises Tuesday, Outperforms Market

Shares of Viatris Inc. (VTRS) fell 1.46% to $16.92 on Monday, underperforming the overall market, which saw the S&P 500 and Dow Jones both rise by 0.19%. This marks the second consecutive day of losses for Viatris, which is now 3.48% below its 52-week high of $17.53 reached on May 8th. Trading volume was 13.6 million, surpassing the 50-day average of 11.4 million.

Viatris Inc. Stock Falls Monday, Underperforms Market

Biocon is actively seeking in-licensing deals to enhance its biosimilars business, aiming to fill portfolio gaps without lengthy in-house development. CEO Shreehas Tambe emphasized the company's established global presence and the need for synergistic external assets. Following the integration of Viatris' biosimilars business, Biocon has commercialized 12 biosimilars and has over 20 in its pipeline. The strategy focuses on accelerating launches and improving asset utilization in a competitive market, with a goal to increase EBITDA margins to 30% in the coming quarters.

Money Control

ALPS Medical Breakthrough

Proshares Ultra Nasdaq Biotech

First Trust NYSE Arca Biotech Index Fd

Invesco Biotechnology & Genome ETF

SPDR S&P Biotech

VanEck Biotech ETF

Direxion S&P Biotech Bull 3X

Biocon eyes in-licensing deals to accelerate biosimilars growth

VIRX

Shares of Viatris Inc. (VTRS) fell 1.27% to $17.17 on Friday, underperforming the overall positive market, with the S&P 500 rising 0.84%. This decline ended a five-day winning streak for the stock, which is now 1.60% below its 52-week high of $17.45 reached on May 7th. Trading volume was 19.5 million, surpassing the 50-day average of 11.3 million.

Viracta Therapeutics

Viatris Inc. Stock Falls Friday, Underperforms Market

Viatris(VTRS.US)